MapLight Therapeutics Reports Strong Cash Position & Key Clinical Milestones, Including Two Phase 2 Readouts in Q3 2026
MPLT sits 48% above its 52-week low of $12.24.
Summary
MapLight Therapeutics reported robust financial results for Q4 and full year 2025, highlighting a strong cash position expected to fund operations through 2027, alongside significant progress in its clinical pipeline with two Phase 2 topline results anticipated in Q3 2026 and a recent FDA Fast Track designation.
Key Events · Earnings and Guidance · MPLT
-
Strong Cash Position and Runway
The company ended 2025 with $453.1 million in cash, cash equivalents, and investments, which is expected to fund operations through 2027, significantly de-risking future financing.
-
Two Phase 2 Topline Results Expected in Q3 2026
Topline results are anticipated for the Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia and the Phase 2 IRIS trial of ML-004 for autism spectrum disorder.
-
FDA Fast Track Designation Received
ML-007C-MA was granted Fast Track designation by the FDA in December 2025 for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis.
-
Pipeline Expansion with ML-055
The company expanded its pipeline with a next-generation M1/M4 muscarinic agonist program, ML-055, with candidate nomination expected in 2026.
Analysis · MPLT · Life Sciences
MapLight Therapeutics has reported a robust financial position with $453.1 million in cash, cash equivalents, and investments, providing a runway expected to fund operations through 2027. This significantly de-risks the company's near-term financing needs, a critical factor for clinical-stage biopharmaceutical companies. The company also announced multiple significant clinical catalysts, including topline results for two Phase 2 trials (ML-007C-MA for schizophrenia and ML-004 for autism spectrum disorder) expected in the third quarter of 2026. Additionally, ML-007C-MA received FDA Fast Track designation for Alzheimer's disease psychosis, which could accelerate its development and review process. While R&D and net losses increased, this is typical for a company advancing multiple clinical programs. The combination of a strong balance sheet and multiple near-term, high-impact clinical readouts positions the company for a potentially transformative year.
At the time of this filing, MPLT was trading at $18.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $823.1M. The 52-week trading range was $12.24 to $21.55. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.